Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 30, 2015 10:20 PM ET

Biotechnology

Company Overview of Adamas Pharmaceuticals, Inc.

Company Overview

Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems in the United States. The company’s lead product candidate ADS-5102, which completed the Phase II/III clinical trial for the treatment of Parkinson's disease, known as levodopa induced dyskinesia. Its product portfolio also includes memantine-based therapeutics, which include Namenda XR, a treatment of moderate to severe dementia associated with Alzheimer's disease; and Namzaric, a once-daily fixed-dose combination of Namenda XR, which is being co-developed with Forest Laboratories, Inc. The company was f...

1900 Powell Street

Suite 750

Emeryville, CA 94608

United States

Founded in 2000

46 Employees

Phone:

510-450-3500

Fax:

510-428-0519

Key Executives for Adamas Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 51
Total Annual Compensation: $748.8K
Chief Operating Officer
Age: 49
Total Annual Compensation: $436.1K
Senior Vice President of Product Development
Age: 62
Total Annual Compensation: $503.0K
Compensation as of Fiscal Year 2014.

Adamas Pharmaceuticals, Inc. Key Developments

Adamas Pharmaceuticals, Inc. Announces the Completion of Recruitment of its Phase 3 EASE LID Study

Adamas Pharmaceuticals, Inc. announced the completion of recruitment of its Phase 3 EASE LID study. EASE LID is a confirmatory trial designed to evaluate the efficacy and safety of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a motor complication associated with the treatment of Parkinson's disease. EASE LID, which is enrolling approximately 120 individuals, is a 26-week multi-center, randomized, double-blind, placebo-controlled study assessing the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. The primary endpoint of EASE LID is a reduction in dyskinesia assessed by change from baseline to week 12 in UDysRS (a tool that assesses the disability and impairment of LID in Parkinson's disease) with a key secondary endpoint being change in ON time without troublesome dyskinesia as measured by patient diaries. Safety and tolerability are also being assessed. In addition to EASE LID, Adamas has two ongoing Phase 3 clinical trials of ADS-5102 for the treatment of LID in individuals with Parkinson's disease. These clinical trials were initiated following the completion of a Phase 2/3 study. Completed Phase 2/3 Trial: EASED, a randomized, placebo-controlled, multi-center study, evaluated patients with Parkinson's disease experiencing troublesome LID. Patients were randomized to receive placebo or to one of three dose levels of ADS-5102. As previously reported, ADS-5102 at 340 mg/day significantly reduced LID as measured by change in UDysRS over eight weeks versus placebo (primary endpoint, p=0.005). In addition, ADS-5102 increased ON time without troublesome dyskinesia by 3.8 hours, with 2.7 hours coming from a reduction in ON time with troublesome dyskinesia. Data also suggested that ADS-5102 was generally well tolerated and reported adverse events were consistent with Parkinson's disease and the known amantadine safety profile. Ongoing Phase 3 Studies: EASE LID 3, which is estimated to enroll approximately 70 patients. The 13-week multi-center, randomized, double-blind, placebo-controlled study will assess the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime. The primary endpoint of EASE LID 3 is a reduction in dyskinesia assessed by changes in UDysRS with a key secondary endpoint being change in ON time without troublesome dyskinesia as measured by patient diaries. EASE LID 2, an open-label safety study, which is also open to patients from EASED, EASE LID and EASE LID 3.

Adamas Pharmaceuticals, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 01:00 PM

Adamas Pharmaceuticals, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 01:00 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Gregory T. Went, Chairman and Chief Executive Officer.

Adamas Pharmaceuticals, Inc. Announces Additional Findings from Phase 2/3 Study Evaluating ADS-5102 for the Treatment of Levodopa-Induced Dyskinesia

Adamas Pharmaceuticals, Inc. announced additional findings from its Phase 2/3 study (EASED) evaluating ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a movement disorder associated with the treatment of Parkinson's disease. Patient diary data were analyzed to characterize the time course of troublesome LID and other Parkinson's disease states during waking hours, synchronized to the patients' wake-up times as well as to elucidate the impact of treatment with ADS-5102. These data showed that troublesome LID was reported throughout the day. After eight weeks of treatment, the majority of ADS-5102-treated patients reported an increase in the quality of ON time by increasing ON time without troublesome LID throughout the morning, afternoon and evening. In contrast, placebo-treated patients reported little change in their dyskinesia. After eight weeks of treatment, the majority of ADS-5102-treated patients reported an increase in the quality of ON time by increasing ON time without troublesome LID throughout the morning, afternoon and evening. ON time is the period when the effects of levodopa provide relief from symptoms of Parkinson's disease. In this post hoc analysis, to better understand motor complications experienced throughout waking hours, a data set was assembled synchronized according to each patient's wake-up time. This analysis included data from patient diaries (n= 62) at baseline and after eight weeks of treatment with either ADS-5102 (n=42, all doses) or placebo (n=20). This analysis revealed that prior to treatment (baseline), study participants experienced, over the course of the day, a complex and dynamic pattern of Parkinson's disease states, including ON time with and without troublesome LID and OFF time. After eight weeks of placebo treatment, there was little change in this pattern. In contrast, the majority of ADS-5102-treated individuals were able to maintain ON time without troublesome LID throughout the waking day, for at least 14 hours after waking up. ADS-5102 was generally well tolerated and reported adverse event terms were consistent with Parkinson's disease and the known amantadine safety profile.

Similar Private Companies By Industry

Company Name Region
BSF AG Research Inc. United States
MitoGenetics, LLC United States
Eleos, Inc. United States
Isotope Solutions Inc United States
Viridax Corporation United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Adamas Pharmaceuticals, Inc., please visit www.adamaspharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.